CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This study was a one-arm, single-center, phase II clinical study. Patients who meet the
enrollment criteria will receive CM082 tablets 150mg once daily (qd) orally (taken within
half an hour after daily breakfast) in combination with JS001 (3mg/kg, once every 2 weeks,
q2w), every 28 days a treatment cycle until the disease progresses, the toxicity is
intolerable, the investigator or subject decides to withdraw, loses to follow up, starts
using other anti-tumor treatments or dies.